Coordinating genome tools through generative AI breaks diagnostic stagnation in neurological diseases

The usual clinical pathway for a child with speech delay, muscle weakness and seizures begins with a series of examinations that end with the most advanced genetic test, whole-exome or whole-genome sequencing. However, the medical report often returns a confusing result indicating the absence of a definitive molecular diagnosis, or classifying the variant as of uncertain significance. This stark contrast between the ability to read billions of genetic symbols and the inability to interpret the actual cause of disease was the focus of scientific discussion at the International Conference of the Saudi Society of Genetic Medicine in Jeddah, held under the theme “From Diagnosis to Therapy in Genomics.”

Dr. Nof Al-Ghanmi, associate professor of artificial intelligence and bioinformatics at King Abdulaziz University and head of the bioinformatics unit at the Institute of Genomic Medicine, presented a technical approach that explains the gap between detecting a variant and confirming a diagnosis. While the human genome differs from the reference at roughly four to five million loci, algorithms narrow the search to a few dozen variants; however, each filtering step carries the risk of mistakenly discarding the disease-causing variant, and the calculations become more complex in neurological disorders where symptoms of different genes overlap and change with age.Reading a DNA sequence does not necessarily mean understanding its biological function within the cell.Reaching a genetic change requires answering three critical questions: does the change alter cellular function, does it explain the patient’s specific symptoms, and is the evidence sufficient to consider it disease-causing.

Instead of relying on a single algorithm, laboratories employ a variety of specialized tools; the AlphaMissense model predicts the impact of a variant on protein structure, SpliceAI tracks RNA splicing, Exomiser compares clinical symptoms with documented diseases, and broader research models such as AlphaGenome forecast the effect of regulatory changes on genome activity. However, using these models as a voting committee does not provide independent evidence, which gave rise to the concept of agentic artificial intelligence proposed by Al-Ghanmi as a software coordinator that links these tools around a patient’s case, calls the appropriate model for each challenge, examines points of deficiency and conflict, and then presents evidence-supported hypotheses to the human physician. This approach demonstrated research value in a study published in Nature in 2026 on the DeepRare system for rare diseases, where the system coordinated more than forty tools and knowledge sources, achieving a first-place correct diagnosis rate of 69.1 percent of cases, compared with roughly 55.9 percent for conventional tools.

This technological framework gains a decisive clinical dimension when it goes beyond initial testing; a negative exome result carries a temporal context rather than a definitive judgment on the case. A study published in Nature Medicine in 2026 documented the application of an automated system to re-analyze data from 4,735 previously unsolved cases, where the algorithms uncovered 241 new diagnoses, representing 5.1 percent, driven by updates to scientific knowledge bases and advances in inference tools.Turning genetic uncertainty into hypotheses testable in the laboratoryIt represents the core of the transformation, as the role of the smart tool shifts from attempting to announce a final diagnosis to guiding the medical team toward the required complementary test, whether that is a parental test or a laboratory analysis of RNA functions.

This pathway reshapes the priorities of hospitals and reference laboratories in Saudi Arabia and the Gulf, as well as genomic research centers in Egypt and the Levant. Investment in genomic tools is no longer limited to purchasing advanced sequencing machines or importing ready-made Western algorithms, because models trained on generic population databases clash with the specificity of local genetic composition. A variant that is classified as rare in a global database may be common among the region’s inhabitants, and familial relatedness rates impose recessive genetic pathways that require entirely different analysis and filtering strategies. The practical regulatory step for health-sector managers and developers is to establish local genomic repositories to protect data and train intelligent agents on them, while opening the archive of previous cases and subjecting it to periodic automated re-analysis models instead of leaving patients in a pool of undiagnosed cases.

The clinical decision remains contingent on the hybrid intelligence system, with software handling the linking and intensive inference while the genetics consultant and treating physician bear responsibility for the final decision and patient care. Shifting from seeking an instant diagnosis at the press of a button to managing genetic investigation intelligently and agently gives neurological clinics in the region a practical ability to turn hundreds of pending cases into clearly defined therapeutic pathways.